Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) SVP Rebecca Peterson unloaded 19,807 shares of the stock on the open market in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $44.02, for a total transaction of $871,904.14. Following the sale, the senior vice president now directly owns 1,321 shares in the company, valued at approximately $58,150. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Jefferies Group initiated coverage on shares of Alkermes Plc in a research note on Friday, May 16th. They set a “buy” rating and a $53.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Friday, May 2nd. They now have a $50.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Alkermes Plc from an “outperform” rating to a “neutral” rating in a research note on Wednesday, April 16th. They now have a $45.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Alkermes Plc currently has a consensus rating of “Hold” and a consensus price target of $47.00.

Shares of Alkermes Plc (NASDAQ:ALKS) traded up 1.64% during mid-day trading on Thursday, hitting $45.21. The stock had a trading volume of 538,469 shares. Alkermes Plc has a 52-week low of $26.47 and a 52-week high of $54.25. The stock has a 50-day moving average of $44.80 and a 200-day moving average of $44.33. The company’s market cap is $6.534 billion.

Alkermes Plc (NASDAQ:ALKS) last released its earnings data on Wednesday, April 30th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.01. The company had revenue of $130.21 million for the quarter, compared to the consensus estimate of $135.79 million. During the same quarter in the previous year, the company posted $0.40 earnings per share. The company’s revenue for the quarter was down 20.3% on a year-over-year basis. Analysts expect that Alkermes Plc will post $0.49 EPS for the current fiscal year.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.